# US 2016/0256461 A1 · Methods for treating hair loss disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256461 A1
- Document ID: US20160256461A1
- Status: Published application
- Kind: A1
- Application number: 15/066,479
- Filed: 2016-03-10
- Published: 2016-09-08
- Earliest claimed: 2010-11-02
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University In the City of New York
- Inventors: Angela M. Christiano; Raphael Clynes
- Web page: https://patentgrep.com/patent/US20160256461A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61Q 7/00: Preparations for affecting hair growth
- A61K 8/41: Amines
- A61K 8/4953: {containing pyrimidine ring derivatives, e.g. minoxidil}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/529: forming part of bridged ring systems
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/63: Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 2800/782: Enzyme inhibitors; Enzyme antagonists
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

## Claims

### Claim 1

A method of treating a hair-loss disorder in a mammalian subject in need thereof, the method comprising administering to the subject an effective amount of an inhibitor of Janus Kinase (Jak)1, Jak2, or Jak3, wherein said inhibitor is LY3009104.

### Claim 2

A method for inducing hair growth in a subject, the method comprising:
(a) administering to the subject an effective amount of a Jak1, Jak2, or Jak3 inhibitor, wherein said inhibitor is LY3009104,
thereby inducing hair growth in the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the hair-loss disorder comprises androgenetic alopecia, telogen effluvium, alopecia areata, telogen effluvium, tinea capitis, hypotrichosis, or hereditary hypotrichosis simplex.

### Claim 4 (depends on 3)

The method of claim 3, wherein the alopecia areata is alopecia totalis or alopecia universalis.

### Claim 5 (depends on 2)

The method of claim 2, wherein the subject suffers from a hair-loss disorder, wherein the hair-loss disorder is selected from—androgenetic alopecia, telogen effluvium, alopecia areata, telogen effluvium, tinea capitis, hypotrichosis, and hereditary hypotrichosis simplex.

### Claim 6 (depends on 5)

The method of claim 5, wherein the alopecia areata is alopecia totalis or alopecia universalis.

### Claim 7 (depends on 1)

The method of claim 1 wherein the hair loss-disorder is androgenetic alopecia.

### Claim 8 (depends on 1)

The method of claim 1 wherein the hair loss-disorder is alopecia areata.

### Claim 9 (depends on 5)

The method of claim 5 wherein the hair loss-disorder is androgenetic alopecia.

### Claim 10 (depends on 5)

The method of claim 5 wherein the hair loss-disorder is alopecia areata.
